The abstract is read at the publisher; the summary is JClub's.
Izalontamab brengitecan improved progression-free survival and overall survival versus chemotherapy in recurrent or metastatic esophageal squamous cell carcinoma after PD-1/PD-L1 inhibitor plus platinum progression, with median PFS 4.17 vs 1.97 months.
- Why it matters: Patients with advanced ESCC that progresses after first-line PD-1/PD-L1 inhibitor plus platinum chemotherapy have limited effective options, leaving a major treatment gap.
- What they did: In a phase 3 open-label randomized trial across 80 hospitals in China, 497 enrolled patients received izalontamab brengitecan (n=249) or physician-selected irinotecan/paclitaxel/docetaxel chemotherapy (n=248), with PFS and OS assessed by blinded independent central review.
- The result: At interim analysis, median OS was 9.79 months with izalontamab brengitecan versus 7.20 months with chemotherapy (HR 0.63; log-rank P<.001), and grade 3+ treatment-related adverse events were 85.1% versus 59.3%.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.